{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:27:24Z","timestamp":1785320844062,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>A growing amount of evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessitating revascularization interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) [2,3]. However, a limited number of studies have evaluated the impact of MASLD on the outcomes of these interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of the PubMed\/MEDLINE and Embase databases was conducted to identify relevant studies from August 2015 to August 2025 using a combination of Medical Subject Headings (MeSH) terms and text words related to MASLD and cardiovascular revascularization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred nineteen papers from the PubMed\/MEDLINE and Embase databases were reviewed. Six met the inclusion criteria (\n<jats:xref>Figure\u00a01<\/jats:xref>). Five studies covered PCI, and one covered CABG. Supplemental information was added using targeted PubMed\/MEDLINE searches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MASLD may pose an increased risk of in-hospital and long-term mortality following PCI. Risks for cardiogenic shock, cardiac arrest, in-stent thrombosis, gastrointestinal bleeding, or invasive mechanical ventilation following PCI may also be increased. Further studies are needed to determine the optimal coronary revascularization method and post-revascularization medical therapy for patients with MASLD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1609071","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:29:01Z","timestamp":1756186141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review"],"prefix":"10.3389","volume":"12","author":[{"given":"Jacob J.","family":"Gries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafeez Ul","family":"Hassan Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J Lipid Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2468-1253(24)00310-8","article-title":"Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease","volume":"10","author":"Gries","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/hep.32534","article-title":"Relationship between NAFLD and coronary artery disease: a Mendelian randomization study","volume":"77","author":"Ren","year":"2023","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/hep4.1199","article-title":"Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis","volume":"2","author":"Kapuria","year":"2018","journal-title":"Hepatol Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12872-021-02060-z","article-title":"Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis","volume":"21","author":"Hsiao","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0186720","DOI":"10.1371\/journal.pone.0186720","article-title":"Severity of coronary artery disease is associated with non-alcoholic fatty liver disease: a single-blinded prospective mono-center study","volume":"12","author":"Friedrich-Rust","year":"2017","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12872-016-0212-8","article-title":"Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka","volume":"16","author":"Perera","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e00011","DOI":"10.14309\/ctg.0000000000000011","article-title":"Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: a matched case\u2013control study","volume":"10","author":"Liu","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes\u2014a UK biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.jacc.2016.01.070","article-title":"Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis","volume":"67","author":"Zeb","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","article-title":"Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2306192","DOI":"10.1080\/07853890.2024.2306192","article-title":"The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis","volume":"56","author":"Lv","year":"2024","journal-title":"Ann Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e14188","DOI":"10.1111\/eci.14188","article-title":"Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: a meta-analysis","volume":"54","author":"De Filippo","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.amjcard.2017.07.107","article-title":"Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction","volume":"120","author":"Keskin","year":"2017","journal-title":"Am J Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3892\/etm.2017.5476","article-title":"Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting","volume":"15","author":"Wang","year":"2018","journal-title":"Exp Ther Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S-1640","DOI":"10.1016\/s0016-5085(24)04230-6","article-title":"Su1561 clinical characteristics and outcomes of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) undergoing percutaneous coronary intervention (PCI). insight from the national inpatient sample","volume":"166","author":"Aboursheid","year":"2024","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jcin.2023.01.132","article-title":"CRT-100.72 adverse clinical outcomes in non-alcoholic fatty liver disease patients with co-existent diabetes Mellitus who required percutaneous coronary intervention","volume":"16","author":"Khokhlov","year":"2023","journal-title":"J Am Coll Cardiol Intv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.amjcard.2015.09.021","article-title":"Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"116","author":"Emre","year":"2015","journal-title":"Am J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e018869","DOI":"10.1161\/JAHA.120.018869","article-title":"Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention","volume":"10","author":"Liu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e17338","DOI":"10.7759\/cureus.17338","article-title":"In-hospital outcomes of patients with non-alcoholic fatty liver disease who underwent percutaneous coronary intervention: a nationwide inpatient sample analysis","volume":"13","author":"Ali","year":"2021","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"ehaa946.1513","DOI":"10.1093\/ehjci\/ehaa946.1513","article-title":"Non-alcoholic fatty liver disease fibrosis score predicts cardiovascular mortality in post percutaneous coronary intervention patients: a 5-years results from observational registry","volume":"41","author":"Lee","year":"2020","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1324890","DOI":"10.3389\/fimmu.2024.1324890","article-title":"Impacts of systemic inflammation response index on the prognosis of patients with ischemic heart failure after percutaneous coronary intervention","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40001-024-01736-4","article-title":"Systemic immune-inflammation index and in-stent restenosis in patients with acute coronary syndrome: a single-center retrospective study","volume":"29","author":"Xie","year":"2024","journal-title":"Eur J Med Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0735-1097(19)31750-4","article-title":"Effect of systemic inflammation on outcomes after complex percutaneous coronary intervention","volume":"73","author":"Camaj","year":"2019","journal-title":"JACC"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/Life14040473","article-title":"Platelet, antiplatelet therapy and metabolic dysfunction-associated steatotic liver disease: a narrative review","volume":"14","author":"Boccatonda","year":"2024","journal-title":"Life"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102217","DOI":"10.1016\/j.rpth.2023.102217","article-title":"Patients with metabolic dysfunction-associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs","volume":"7","author":"van den Boom","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"B34","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/nu16070920","article-title":"Ticagrelor, but not clopidogrel, attenuates hepatic steatosis in a model of metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Lee","year":"2024","journal-title":"Nutrients"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1496639","DOI":"10.3389\/fphar.2024.1496639","article-title":"Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond","volume":"15","author":"Tai","year":"2024","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review","volume":"329","author":"Tapper","year":"2023","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1467-789X.2001.00044.x","article-title":"Use of beta-blockers in obesity hypertension: potential role of weight gain","volume":"2","author":"Pischon","year":"2001","journal-title":"Obes Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9392","DOI":"10.3390\/ijms21249392","article-title":"Effect of adrenergic agonists on high-fat diet-induced hepatic steatosis in mice","volume":"21","author":"Nakade","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bbrc.2013.07.005","article-title":"Propranolol, a \u03b2-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis","volume":"437","author":"McKee","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101453","article-title":"Patient management following percutaneous coronary intervention","volume":"4","author":"Wennberg","year":"2025","journal-title":"JACC Adv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1609071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:29:02Z","timestamp":1756186142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1609071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":42,"alternative-id":["10.3389\/fcvm.2025.1609071"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1609071","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1609071"}}